Siemens Healthineers has lowered its revenue guidance for the current fiscal year, marking the second consecutive downgrade for the medical technology giant.
The Munich-based company attributed the revised outlook to continued underperformance in its lab diagnostics segment, a business unit that is already listed for sale.
The decision underscores the depth of the headwinds facing the division.
Despite the ongoing sale process, the lab diagnostics unit continues to drag on the group's overall financial trajectory, forcing management to adjust expectations for the fiscal year ending in September 2026.
The repeated guidance cuts signal that the integration or separation challenges in this segment are more severe than previously anticipated.
This development follows a broader pattern of caution among German industrial and healthcare firms.